Article Text

Download PDFPDF

Population-based study of lung function and incidence of heart failure hospitalisations
Free
  1. Gunnar Engström,
  2. Olle Melander,
  3. Bo Hedblad
  1. Department of Clinical Sciences, Lund University, Malmö University Hospital, Sweden
  1. Correspondence to Professor Gunnar Engström, Cardiovascular Epidemiology Research Group, UMAS, CRC, 20502 Malmö, Sweden; Gunnar.Engstrom{at}med.lu.se

Abstract

Background Reduced forced expiratory volume (FEV1) and forced vital capacity (FVC) are risk factors for myocardial infarction (MI) and stroke. However, the relationship with incidence of heart failure (HF) is incompletely known. This population-based study explored whether reduced FEV1 or FVC is associated with the incidence of hospitalisation for HF.

Methods 20 998 men (mean age 43 years) with no history of MI or stroke were examined with spirometry in 1974–84. The incidence of hospitalisation due to HF was studied over a mean follow-up of 23 years in relation to age- and height-adjusted FEV1 and FVC.

Results 725 incident HF hospitalisations occurred during the follow-up period, 503 of them without a previous or concurrent diagnosis of MI. In non-smokers the risk factor-adjusted hazard ratio (HR) for HF hospitalisation was 1.25 (95% CI 1.11 to 1.40) and 1.26 (95% CI 1.13 to 1.42), respectively, per 1SD lower FEV1 and FVC. The corresponding risk factor-adjusted HRs in smokers were 1.32 (95% CI 1.21 to 1.45) and 1.22 (95% CI 1.11 to 1.33), respectively, for FEV1 and FVC. This relationship was consistent in men with and without hypertension, in men above and below the median age of 44 years and for HF events without previous or concurrent MI. Exclusion of cases with a diagnosis of chronic obstructive pulmonary disease during the follow-up period did not substantially change the results.

Conclusion In this long-term population-based study of men, moderately reduced FEV1 and FVC were associated with an increased incidence of hospitalisations due to HF.

  • Clinical epidemiology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding This study was supported by grants from the Swedish Heart and Lung Foundation, the Swedish Research Council, Lund University and Malmö University Hospital.

  • Competing interests GE is employed as a senior epidemiologist by AstraZeneca R&D.

  • Ethics approval This study was conducted with the approval of the regional ethics commitee, Lund University, Sweden. The health service authority of Malmö approved and funded the screening programme. All participants gave informed consent. The data linkage with hospitalisation registers was approved by the regional ethics committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.